Davis Polk is advising Biotie Therapies Corp. in connection with its combination agreement with Acorda Therapeutics, Inc. where Acorda will make a public tender offer in Finland and the…
Davis Polk advised Sumitomo Mitsui Banking Corporation in connection with a medium-term note program update and a benchmark takedown, which consisted of $750 million aggregate principal…
Davis Polk advised the initial purchasers of a Regulation S offering of high-yield notes by Evergrande Real Estate Group Limited of $300 million aggregate principal amount of its 8.0%…
Davis Polk is advising the dealer managers in connection with cash tender offers by ERP Operating Limited Partnership, an operating partnership subsidiary of Equity Residential (the …
Davis Polk is advising Arch Coal, Inc. (“Arch”) in connection with its restructuring under chapter 11 of the Bankruptcy Code, a $275 million debtor-in-possession (DIP) financing facility…
Davis Polk advised the joint book-running managers in connection with an $86.2 million SEC-registered follow-on common stock offering of 8,625,000 shares of common stock for Ardelyx, Inc…
Davis Polk advised the joint book-running managers of an SEC-registered offering by Black Hills Corporation of $250 million aggregate principal amount of its 2.500% notes due 2019 and $300…
Davis Polk advised the underwriters in connection with an SEC-registered Schedule B debt offering by The Korea Development Bank of $500 million aggregate principal amount of its 2.5% notes…
Davis Polk advised the joint book-running managers in connection with a $66.1 million SEC-registered common stock offering of 2,875,000 shares of common stock of Adamas Pharmaceuticals, Inc…
Davis Polk advised the underwriters in connection with the SEC-registered offering of 4,166,167 shares of common stock of Cempra, Inc. The net proceeds to Cempra were approximately $93.7…